Researchers at a group of big drug companies, including GSK, Takeda and Novartis, have begun to study whether drugs currently prescribed to treat diabetes can be used to prevent the disease. The winners in this field can potentially open up a huge new market for drugs that already offer a good safety profile. Amylin and Eli Lilly are both active here as well. Some analysts peg the market for diabetes-prevention at $15 billion. Some 54 million Americans are considered pre-diabetic.
- read The Wall Street Journal report on diabetes therapies (sub. req.)